key: cord-1042800-wje79vsh authors: Min, Young Gi; Ju, Woohee; Ha, Ye-Eun; Ban, Jae-Jun; Lee, Seolah; Sung, Jung-Joon; Shin, Je-Young title: Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature date: 2021-08-08 journal: J Neuroimmunol DOI: 10.1016/j.jneuroim.2021.577691 sha: 8ac4b26834f8e66ed80ba69eb51a69d0ed1bebf1 doc_id: 1042800 cord_uid: wje79vsh Massive vaccination against COVID-19 has become a global priority. Simultaneously, concerns regarding the safety of vaccines are growing. We describe two patients who developed sensory Guillain-Barre syndrome (GBS) shortly after the first dose of the ChAdOx1 vaccine. We also summarize 12 published cases of GBS after ChAdOx1 vaccination, highlighting their unique clinical and paraclinical features. We propose a possible association between the risk of GBS and the ChAdOx1 vaccine and recommend surveillance for GBS following vaccination. Population-based studies are needed to determine causality and whether specific subpopulations are susceptible. Massive vaccination against severe acute respiratory coronavirus-2 (SARS-CoV-2) has become a global priority. However, concerns regarding the safety of COVID-19 vaccines are growing. For example, a causal relationship between the ChAdOx1 vaccine and thrombotic immune thrombocytopenia was recently established (Cines and Bussel, 2021) . Among the A 37-year-old woman without any previous medical history and infections developed tingling sensations over both lower extremities four days after receiving her first dose of the ChAdOx1 vaccine. Afterwards, we developed painful cold sensations, and symptoms got worse over the next two weeks. Neurological examination on the 25th post-vaccination day revealed cold hypoesthesia in both legs, especially in the feet and posterior calf. The MRC grades and DTRs were normal in all four limbs. NCS, spine MRI, ultrasonography, and computed tomography angiography of the lower extremities were normal. However, a decrease in the distal leg IENFD demonstrated a small fiber neuropathy (Fig. 1B) . Furthermore, the quantitative sudomotor axon reflex was abnormal in the right forearm and low normal in the right calf (Fig. 1E ). The following laboratory tests were normal or negative: GM1, GD1b, GQ1b IgG/IgM, MAG IgM, anti-nuclear antibodies, anti-neutrophil cytoplasmic antibodies, complement levels, serum electrophoresis with immunofixation, hemoglobin A1c, folate, thiamine, thyroid function test, D-dimer, and HIV antibody. Her symptoms moderately improved with gabapentin, duloxetine, and tramadol. Nasopharyngeal swabs were negative for SARS-CoV-2 on the RT-PCR test. every tested patient (0/10). Ten patients received IVIg and/or plasma exchange, mostly leading to a partial recovery. A causal relationship between COVID-19 and GBS is under active discussion since the first report on their co-occurrence in January 2020 (Dalakas, 2020 , Fantini et al. , 2020 , Keddie et al. , 2021 , Palaiodimou et al. , 2021 , Zhao et al. , 2020 . A large-scale population-based study reported that the incidence of the whole GBS did not increase during the pandemic (Keddie, Pakpoor, 2021) . However, a recent meta-analysis based on 11 cohorts found an increased risk of the demyelinating subtype in COVID-19 patients compared to non-infected or historical counterparts (Palaiodimou, Stefanou, 2021) . Conversely, little is known about the relationship between COVID-19 vaccines and GBS. No GBS occurred in clinical trials of COVID-19 vaccines, except for one among 19,630 Ad26.COV2.S recipients (Baden et al. , 2021 , Heath et al. , 2021 , Polack et al. , 2020 , Sadoff et al. , 2021 , Voysey et al. , 2021 . Although rare, we propose a possible association between GBS and the ChAdOx1 vaccine. The frequent observation of rare variants and demyelinating subtypes, which increased in COVID-19 GBS, further supports our suspicion. However, the pathophysiological mechanisms underlying this vaccine-associated neuro-autoimmunity remain elusive; whether antibodies against the spike protein could cross-react with peripheral nerve constituents is controversial (Dalakas, 2020 , Fantini, Di Scala, 2020, Keddie, Pakpoor, Vaccination information in South Korea Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription Assessment of current diagnostic criteria for Guillain-BarrĂ© syndrome Guillain-Barré Syndrome in a 67-year-old Male Post COVID-19 Vaccination Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. The New England journal of medicine Guillain-Barre syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. The New England journal of medicine Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome Diagnosis and management of Guillain-Barre syndrome in ten steps Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 Vaccine Prevalence, clinical characteristics and outcomes of Guillain-Barre syndrome spectrum associated with COVID-19: A systematic review and meta-analysis Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine